South Korean publicly listed bioscience companies in 2013 registered combined revenue of $8.3 billion.

The leading publicly listed bioscience company in South Korea, Yuhan Corporation, clocked $825.6 million in revenue.

Some of the key developments in the country included:
Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, expanded collaboration to develop, manufacture and commercialize MK-1293

Korea and Singapore scientists jointly studied RUNX3, a gene that is intensively studied for its function as a tumour suppressor, and analysed that it is also likely to be a key and critical component of the body's first line of defence against lung cancer development.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) collaborated with Agilent Technologies to launch DGIST's new Neurometabolomics Excellence Research Center for early detection and diagnosis of brain diseases.

The government implemented new policies giving tax breaks for research and development costs and established a R&D fund for the pharmaceutical market.

SOUTH KOREA: TOP 20 BIOSCIENCE COMPANIES